On 1 December WHO is calling on global leaders and citizens to rally for “global solidarity” to maintain essential HIV services during COVID 19 and beyond – and to ensure continued provision of HIV services for children, adolescents
and populations most at risk for the disease. The Organization also calls on countries to provide health workers with greater protection and support so they can continue their work safely during the pandemic.
Protecting people from HIV during the pandemic, and ensuring they can maintain treatment, is critical. Researchers are currently investigating whether people with HIV have an increased risk of poor outcomes with COVID-19. A preliminary analysis of hospitalized
people with COVID-19 from 21 countries reported to the WHO Global COVID-19 Clinical Data Platform reveals that among the 61 414 people hospitalized with suspected or confirmed COVID-19 infection, 5 291 (8.6%) have an HIV positive status which was found to increase the risk for death when adjusted for severity of illness, age, gender and comorbidity burden; the absolute risk for all in the analysis was low.
This preliminary evidence of moderate increased vulnerability of people with HIV makes it even more urgent that people with HIV have access to antiretrovirals (ARVs) and treatments for co-morbidities – such as treatment
for non communicable diseases (NCDs), chronic obstructive pulmonary disease (COPD), diabetes and tuberculosis.
WHO and partners sounded the alarm earlier this year, concerned at the impact of reported disruptions in service delivery. But now, thanks to the unstinting work of health and community workers, the number of countries reporting disruptions in HIV
services has declined by almost 75% since June. Only 9 of the 152 countries surveyed are still reporting disruptions (maps: June 2020 – November 2020); and in June, 24 countries reported less than 3 months supply of ARVs, while now only
12 report a critically low stock.
This is mainly due to the implementation of existing guidelines, including providing multi-month dispensing (MMD) of ARVs for 3-6 months to patients who did not have access to health facilities; strong WHO-led global, regional, country, manufacturer
and partner coordination to ensure adequate supply of drugs stocks, and sustained provision of facility-based essential health services and community delivery mechanisms.
But countries have also introduced a number of effective adaptations and innovations in service delivery during COVID-19. These include:
- In many countries in sub-Saharan Africa, testing for COVID-19 has heavily relied on the laboratory systems built and developed by HIV and TB programs. Devices have been shared across programs as well as infrastructure, sample transport systems,
and highly skilled staff.
- In Thailand, PrEP services have been delivered through key population led health services providing multi-month dispensing, telehealth, Xpress service, self-sampling, and counselling.
- In Bulgaria, a demonstration project showed strong community demand for HIV self-testing which also led to expansion of testing services to reduce inequalities between rural and urban areas.
“On World AIDS Day 2020, we pay tribute to the communities and countries who have shown resilience and innovation – often spearheaded by people themselves living with HIV,“ says Dr Meg Doherty, Director of WHO’s Department of Global
HIV, Hepatitis and STI Programmes. “This is vital, because while we focus on fighting this new pandemic, we must not drop our guard on a twin pandemic that has been with us for 40 years and which is far from over.”
Progress towards global targets for diagnosis and treatment has slowed down considerably this year.
New data shows that an estimated 26.0 million people were on antiretroviral treatment as of mid-2020, up only 2.4%
from an estimate of 25.4 million at the end of 2019. This increase is too slow by comparison to last year where treatment coverage increased by an estimated 4.8% between January and June of 2019. Among 24 countries with monthly data reported
to UNAIDS and WHO, people currently on treatment have been supported and maintained, but testing has declined in all and newly enrolled on treatment has been halved. In the last few months; however, there positive signs of rebound in testing and
WHO hopes that some of the innovative approaches adopted during COVID-19 can help the world catch up and accelerate progress towards our new 2025 targets and the SDG goals of ending AIDS as a public health threat by 2030.